Cardiac biomarkers, particularly high-sensitivity cardiac troponins (hs-cTn) and natriuretic peptides (BNP or NT-proBNP), are crucial tools in the early detection and monitoring of cancer-therapy-related cardiovascular toxicity. This evidence concerns the gene NPPB and cancer.